Otros idiomas NKGen Biotech, Inc. Nyse

Acciones

NKGN

US65488A1016

Diferido Nyse Otros sitios de cotización 17:39:22 17/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,12 ^USD	-0,89 %		-10,40 %	-86,51 %

29/04	Nkgen Biotech anuncia la autorizaciýn de la FDA de la solicitud de Nuevo Fýrmaco en Investigaciýn (IND, por sus siglas en inglýs) para la terapia de cýlulas NK SNK01 en la enfermedad de Parkinson	CI
18/04	NKGen Biotech, Inc. anuncia su prýxima presentaciýn sobre la terapia de cýlulas NK SNK01 en enfermedades neurodegenerativas en la 12ý Cumbre Anual para el Desarrollo de Fýrmacos contra el Alzheimer y el Parkinson	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition	16/05
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease	29/04
Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	29/04
NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP	29/04
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	25/04
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology Annual Meeting	25/04
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24/04
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's and Parkinson's Drug Development Summit	19/04
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	18/04
NKGen Biotech, Inc. Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit	18/04
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs	11/04
NKGen Biotech, Inc. announced that it has received $5 million in funding	05/04
NKGen Biotech, Inc. announced that it has received $0.5 million in funding from AJB Capital Investments LLC, Sandia Investment Managment LP, Diametric Capital, LP	01/04
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's disease at the Tau2024 Global Conference	26/03
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference	25/03
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer?s Disease At the Tau2024 Global Conference	25/03
NKGen Biotech, Inc. announced that it expects to receive $0.33 million in funding from FirstFire Capital Management LLC	21/03
NKGen Biotech, Inc. Announces Resignation of Sangwoo Park as Chairperson of the Board	20/03
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference	04/03
NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee	08/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas NKGen Biotech, Inc. Nyse

Acciones

NKGN

US65488A1016

Otros idiomas

Filtros